Multiple locations
Saint Paul, Minnesota, 55112, United States
NCT Number: NCT00387803
The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.
Looking for future studies?
Notify MeAll sexes
Interventional
Phase 2 / Phase 3
Saint Paul, Minnesota, 55112, United States
Patients enrolled received a device with cardiac resynchronization therapy (CRT) and defibrillation. Patients were randomized to CRT on or off for up to six months and evaluated for mortality, hospitalization, and functional outcomes including exercise capacity, quality of life, symptomatic status, and echocardiographic analysis.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Boston Scientific Corporation
Industry
VENTAK CHF/CONTAK CD Biventricular Pacing Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02729922
Cardiovascular Diseases, Heart Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT00400985
Cardiovascular Diseases, Disease
Antwerp, Belgium
View Trial DetailsNCT00262119
Arrhythmias, Cardiac, Atrial Fibrillation
Rome, Italy
View Trial DetailsNCT04283994
Brain Diseases, Cardiovascular Diseases
Seattle, Washington, United States
View Trial Details